322 related articles for article (PubMed ID: 7530128)
21. [Recurrence following radical surgery for prostatic cancer. Analysis of clinical, biological and anatomo-pathological prognostic factors].
Feyaerts A; Delrée A; Lorge F; Opsomer RJ; Wese FX; Van Cangh PJ; Draguet AP; Cosyns JP
Acta Urol Belg; 1997 Mar; 65(1):11-8. PubMed ID: 9245198
[TBL] [Abstract][Full Text] [Related]
22. Invasion of seminal vesicles by adenocarcinoma of the prostate: PSA outcome determined by preoperative and postoperative factors.
Bloom KD; Richie JP; Schultz D; Renshaw A; Saegaert T; D'amico AV
Urology; 2004 Feb; 63(2):333-6. PubMed ID: 14972484
[TBL] [Abstract][Full Text] [Related]
23. Neoadjuvant androgen deprivation therapy before radical prostatectomy: who is unlikely to benefit?
Rabbani F; Sullivan LD; Goldenberg SL; Stothers L
Br J Urol; 1997 Feb; 79(2):221-5. PubMed ID: 9052474
[TBL] [Abstract][Full Text] [Related]
24. Eliminating the need for per-operative frozen section analysis of pelvic lymph nodes during radical prostatectomy.
Bangma CH; Hop WC; Schröder FH
Br J Urol; 1995 Nov; 76(5):595-9. PubMed ID: 8535678
[TBL] [Abstract][Full Text] [Related]
25. Prostate specific antigen progression in men with lymph node metastases following radical prostatectomy: results of long-term followup.
Palapattu GS; Allaf ME; Trock BJ; Epstein JI; Walsh PC
J Urol; 2004 Nov; 172(5 Pt 1):1860-4. PubMed ID: 15540739
[TBL] [Abstract][Full Text] [Related]
26. Probability of biochemical recurrence by analysis of pathologic stage, Gleason score, and margin status for localized prostate cancer.
Khan MA; Partin AW; Mangold LA; Epstein JI; Walsh PC
Urology; 2003 Nov; 62(5):866-71. PubMed ID: 14624910
[TBL] [Abstract][Full Text] [Related]
27. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
28. Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer: results of a phase II study.
Cookson MS; Sogani PC; Russo P; Sheinfeld J; Herr H; Dalbagni G; Reuter VE; Begg CB; Fair WR
Br J Urol; 1997 Mar; 79(3):432-8. PubMed ID: 9117227
[TBL] [Abstract][Full Text] [Related]
29. [Clinicopathological study of prostate cancer patients who had a serum PSA level of more than 20 ng/ml and were treated by a radical prostatectomy].
Udo K; Otsubo S; Sakamoto N; Iguchi A
Nihon Hinyokika Gakkai Zasshi; 2007 Jul; 98(5):685-90. PubMed ID: 17682447
[TBL] [Abstract][Full Text] [Related]
30. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy.
Trapasso JG; deKernion JB; Smith RB; Dorey F
J Urol; 1994 Nov; 152(5 Pt 2):1821-5. PubMed ID: 7523728
[TBL] [Abstract][Full Text] [Related]
31. Induction androgen deprivation therapy before radical prostatectomy for prostate cancer--initial results.
Abbas F; Kaplan M; Soloway MS
Br J Urol; 1996 Mar; 77(3):423-8. PubMed ID: 8814850
[TBL] [Abstract][Full Text] [Related]
32. Periprostatic tissues intraoperative frozen section during retrograde radical retropubic prostatectomy.
Fasolis G; Degiuli P; Lancia M; Fasolo PP; Conti E; Sebastiani G; Lacquaniti S
Arch Ital Urol Androl; 2006 Sep; 78(3):107-11. PubMed ID: 17137025
[TBL] [Abstract][Full Text] [Related]
33. Natural history of disease progression in patients who fail to achieve an undetectable prostate-specific antigen level after undergoing radical prostatectomy.
Rogers CG; Khan MA; Craig Miller M; Veltri RW; Partin AW
Cancer; 2004 Dec; 101(11):2549-56. PubMed ID: 15470681
[TBL] [Abstract][Full Text] [Related]
34. Early surgical results with intent to treat by radical retropubic prostatectomy for clinically localized prostate cancer.
Abbas F; Siddiqui K; Biyabani SR; Hasan SH; Talati J
J Pak Med Assoc; 2002 May; 52(5):200-5. PubMed ID: 12174491
[TBL] [Abstract][Full Text] [Related]
35. Adjuvant radiation, chemotherapy, and androgen deprivation therapy for pathologic stage D1 adenocarcinoma of the prostate.
Freeman JA; Lieskovsky G; Grossfeld G; Esrig D; Stein JP; Cook DW; Petrovich Z; Chen SC; Groshen S; Skinner DG
Urology; 1994 Nov; 44(5):719-25. PubMed ID: 7526528
[TBL] [Abstract][Full Text] [Related]
36. Disease progression and survival in patients with prostate carcinoma and positive lymph nodes after radical retropubic prostatectomy.
Kroepfl D; Loewen H; Roggenbuck U; Musch M; Klevecka V
BJU Int; 2006 May; 97(5):985-91. PubMed ID: 16643480
[TBL] [Abstract][Full Text] [Related]
37. A review of radical prostatectomy from three centres in the UK: clinical presentation and outcome.
Feneley MR; Gillatt DA; Hehir M; Kirby RS
Br J Urol; 1996 Dec; 78(6):911-8; discussion 919-20. PubMed ID: 9014719
[TBL] [Abstract][Full Text] [Related]
38. Radical prostatectomy as a monotherapy for locally advanced (stage T3) prostate cancer.
van den Ouden D; Davidson PJ; Hop W; Schröder FH
J Urol; 1994 Mar; 151(3):646-51. PubMed ID: 7508523
[TBL] [Abstract][Full Text] [Related]
39. Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers.
Noguchi M; Stamey TA; McNeal JE; Yemoto CM
J Urol; 2000 Nov; 164(5):1596-600. PubMed ID: 11025712
[TBL] [Abstract][Full Text] [Related]
40. PSA levels and the rate of positive surgical margins in radical prostatectomy specimens preceded by androgen blockade in clinical B2 (T2bNxMo) prostate cancer. The Lupron Depot Neoadjuvant Study Group.
McLeod DG; Johnson CF; Klein E; Peabody JO; Coffield S; Soloway M
Urology; 1997 Mar; 49(3A Suppl):70-3. PubMed ID: 9123740
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
